Key Developments
Envision Green (01783) has allocated HK$1.288 billion to acquire high-performance servers, expanding its footprint in the cloud computing and intelligent computing sectors. Nuobikan (02635) entered into a software sales agreement with a domestic AI chip company valued at RMB 50.8 million. A subsidiary of Tsaker New Energy (01986) plans to invest RMB 51.26 million to form a joint venture with Zijin Lithium-Yuan, focusing on the R&D, production, and sale of iron phosphate. Nasun Technology (02261) saw its Hong Kong public offering oversubscribed by 2,513.54 times, with net proceeds from the global offering reaching approximately HK$533 million. Bank of Jiangxi (01916) intends to issue up to 715 million domestic shares and 215 million H shares via special mandate non-public placement. Transcenta Holding (06628) plans to sell its CDMO assets for RMB 190 million. Shijiazhuang Yiling Pharmaceutical (02005) has obtained production registration approvals for four products, including Potassium Chloride Injection (II) (100ml:1.5g) and Sodium Hyaluronate Eye Drops 0.3% (0.4ml:1.2mg). Sino Biopharmaceutical (01177) received approval for the launch of its second-generation Flurbiprofen patch. Shanghai Haohai Biological Technology (06826) announced that its controlled subsidiary’s trifocal toric intraocular lens product has obtained medical device registration certification. Jennewein Biotechnologie (02617) reported that Jente (Tenegotinib tablets) received marketing approval from the National Medical Products Administration. Jiangsu Hengrui Medicine (01276) secured approval for a fifth new indication for its independently developed Class 1 innovative drug Ivarmacitinib Sulfate Tablets (SHR0302). Additionally, a third indication for Jiangsu Hengrui Medicine’s (01276) injectable Recombinant Herceptin was approved for market. Yiteng Jiahe (06998) announced that the first patient has been dosed in its GB268 Ib/II phase clinical trial.
Share Buybacks and Stake Changes
Chaozhou Three-Circle Group (06951) spent RMB 160 million on August 6 to repurchase 1.2894 million A-shares. Xiaomi Corporation (01810) used HK$49.9504 million on August 6 to buy back 1.862 million shares. Midea Group (00300) invested RMB 40.023 million on August 6 to repurchase 469,600 A-shares. Longcheer Technology (09611) spent approximately RMB 19.9958 million on August 6 to repurchase 546,200 A-shares. Anhui Conch Cement (00914) used RMB 17.7139 million on August 6 to buy back 1 million A-shares.
Operational and Financial Results
Pacific Basin Shipping (02343) reported an interim net profit attributable to shareholders of US$105 million, a 310.35% year-on-year increase. MGM China Holdings (02282) posted an interim profit attributable to owners of approximately HK$1.9 billion, a 20.24% decline year-on-year. Zai Lab (09688) recorded total revenue of US$206 million in the first half of the year. Beijing Biocytogen (02315) issued a profit alert, expecting a net profit attributable to shareholders of RMB 236 million to RMB 246 million for the first half of the year, representing a 391.87% to 412.71% surge year-on-year. Mongolian Mining Corporation (00975) issued a profit alert, forecasting a consolidated net profit of approximately US$100 million to US$110 million for the first half of the year, turning around from a loss in the prior period. Lingbao Pharmaceutical (09637) issued a profit alert, noting that first-half revenue soared over seven-fold and losses narrowed significantly, highlighting strong growth potential. China Overseas Land & Investment (00688) reported cumulative contracted property sales of approximately RMB 149.47 billion for the first seven months, a 13.2% year-on-year increase. China Overseas Grand Oceans Group (00081) saw cumulative contracted sales of RMB 22.073 billion for the first seven months, up 18.4% year-on-year. Poly Property Group (00119) achieved cumulative contracted sales of approximately RMB 26.2 billion for the first seven months, an 11.19% decrease year-on-year. Greentown China (03900) reported total contracted sales of approximately RMB 107 billion for the first seven months, down 21.78% year-on-year. Gemdale Properties and Investment Corporation (00535) posted cumulative contracted sales of approximately RMB 3.983 billion for the first seven months, a 42.94% decline year-on-year.
Comments